Amatore F, Ortonne N, Lopez M, Barre M, Orlanducci F, Castellano R, Ingen-Housz_Oro S, De Croos A, Gorvel L, Goubard a< Boubdallah R, De Colella JMC, Grob JJ, Gaulard P, Bagot M, Bensussan A, Delaporte E, Olive D (2021) ICOS is widely expressed in cutaneous T-cell Lyphoma and its targeting promotes potent killing of malignant cells. Blood 138(s1):790 792. doi: 10.1182/blood-2021-150677
Objective: To investigate inducible Co-Stimulator (ICOS), a T-cell co-stimulatory receptor involved in the development of cutaneous T-cell lymphomas (CTCLs).
Summary: ICOS is a promising therapeutic target because it is expressed both by tumor T-cells and regulatory T-cells. Authors report for the first time the strong and frequent expression of ICOS in CTCLs, as well as the preclinical efficacy of anti-ICOS ADCs on a CTCL cell line and Patient Derived Xenografts (PDXs).
Usage: The secondary conjugate, Mab-ZAP (IT-04), was used to determine the ability of the antibody to act as an antibody-drug conjugate.
Related Products: Mab-ZAP (Cat. #IT-04)